The authors found that SNP rs1625649 in the O6-Methylguanine-DNA methyltransferase (MGMT) gene, involved in direct reversal repair, significantly impaired OS of CRC patients treated with oxaliplatin-based therapy, but the combined A/G + G/G genotype of the MSH2 rs3732183 (c.1661+12G>A) was associated with better OS (p = 0.02) [157]. This evidence concerns the gene MSH2 and colorectal carcinoma.